Editas Medicine announced a three-year, $5 million agreement with Cystic Fibrosis Foundation Therapeutics recently, and Caribou Biosciences completed a $30 million Series B financing round.
Editas announces the first quarter performance report, new trade diving the development of CRISPR/Cas9 treatment
Among the leading companies in CRISPR field, Editas firstly carried out IPO, and announced the first quarter performance report. By 31st March this year, the total cash and cash equivalents reached $229.2 million, which including the $97.70 billion collected from the IPO in February this year.
Cystic Fibrosis Foundation Therapeutics (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, will pay Editas Medicine up to $5 million to support the discovery and development of CRISPR/Cas9-based medicines for the treatment of cystic fibrosis (CF). In addition, Editas will access CFFT’s extensive network of CF scientific advisers and clinical researchers.
Jennifer Doudna“CRISPR”Series B financing gathered $30 million
The patent dispute between Jennifer Doudna and Zhang Feng caused the break of their partnership. Jennifer was one of the co-founder of Editas, until Zhang successfully applied the patent, Jennifer left and authorized her intellectual property right to the company Intellia Therapeutics, at the same time, Jennifer founded her own company Caribou Biosciences. Early in 2015, the pharmaceuticals industry giant Novartis, established the cooperating relationship with Intellia and Caribou simultaneously.
In other CRISPR news, Caribou Biosciences announced the completion of a $30 million Series B financing round this morning. The financing included the participation of new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech. Also participating in the round were existing investors, including F-Prime Capital Partners, Novartis, Mission Bay Capital, and 5 Prime Ventures. Philip Austin, Founding Partner at Anterra Capital, has joined the company's Board of Directors, representing the Series B investor class.
